Ann: Transcript of CAN-003 data conference call , page-21

re: Ann: Transcript of CAN-003 data conferenc... Got this from BLT forum : So where we stand

and prep to start PIII trial for Ovarian Cancer adjuvant Fang (shRNA) Therapy:

"
DALLAS, June 4, 2014 (GLOBE NEWSWIRE) -- Gradalis Inc., a late stage clinical company, today announced that Scott Gottlieb, MD has joined its board of directors. Dr Gottlieb, MD is a practicing physician and Resident Fellow at the American Enterprise Institute. From 2005-2007, Dr. Gottlieb served as the Deputy Commissioner of the Food and Drug Administration and before that, from 2003-2004, as a senior medical technology advisor to the FDA Commissioner and as the FDA's Director of Medical Policy Development. He left FDA in the spring of 2004 to work on implementation of the new Medicare Drug Benefit as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services.

...

"We are pleased that Dr Gottlieb has joined our board and we look forward to his advice and guidance as we initiate our Phase 3 program in ovarian cancer for our personalized cancer immunotherapy." said Joseph M. Limber, President and Chief Executive Officer of Gradalis. "I look forward to this exciting time in the advancement of novel immunotherapies for the treatment of patients with cancer. We are clearly on the leading edge of medicines to help even more patients with this deadly disease".

The Gradalis personalized immunotherapy Phase 3 program will focus on the adjuvant treatment of patients with stage III/IV ovarian cancer after surgical debulking and six weeks of chemotherapy. There are currently no therapies approved for this setting. The ovarian cancer program is the first of several development directions employing this personalized immunotherapy. The other planned programs will be in the treatment of hepatocellular carcinoma, colorectal cancer with liver metastases, and Ewing's sarcoma.
"

http://globenewswire.com/news-release/2014/06/04/641833/10084037/en/Gradalis-Inc-Announces-Dr-Scott-Gottlieb-Joins-Board-of-Directors.html